Light-chain (AL) amyloidosis · 14 regimens
Cost vs Efficacy · 5 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Daratumumab monotherapy Variant #03 | — | R 366 888 | 28d | — | — | — | — | 1 |
Thalidomide and Dexamethasone (TD) Variant #12 | — | R 57 486 | 29d | ~18.6 mo | ~63.2 mo | ~20 | ~R 1 149 724 PFS proxy · indirect | 3 |
Ixazomib monotherapy Variant #04 | — | R 57 453 | 28d | ~22.0 mo | — | ~24 | ~R 1 378 872 PFS proxy · indirect | 2 |
CTD Variant #02 | — | R 42 203 | 28d | — | — | — | — | — |
Ixazomib and Dexamethasone Variant #01 | — | R 33 178 | 28d | — | — | — | — | — |
Lenalidomide and Dexamethasone (Rd) Variant #09 | — | R 14 094 | 35d | ~21.0 mo | ~55.4 mo | ~19 | ~R 267 783 PFS proxy · indirect | 27 |
Bortezomib monotherapy Variant #14 | — | R 8 539 | 35d | ~30.3 mo | — | ~27 | ~R 230 565 PFS proxy · indirect | 5 |
Bendamustine and Dexamethasone Variant #01 | — | R 6 369 | 28d | — | — | — | — | — |
Lenalidomide and Dexamethasone (RD) Variant #01 | — | R 5 879 | 28d | — | — | — | — | — |
CRd Variant #07 | — | R 4 002 | 28d | — | — | — | — | — |
Melphalan and Dexamethasone Variant #05 | — | R 1 487 | 42d | — | ~45.5 mo | — | — | 2 |
Dexamethasone monotherapy Variant #11 | — | R 1 389 | 35d | — | — | — | — | — |
Cyclophosphamide and Dexamethasone Variant #01 | — | R 384 | 28d | — | ~10.0 mo | — | — | 1 |
Pomalidomide and Dexamethasone (Pd) N/A - secondary systemic drug | — | R 0 | 28d | ~6.5 mo | ~17.4 mo | ~8 | ~R 0 PFS proxy · indirect | 13 |
14 of 14 regimens shown